For example, the Nivolumab trial used the anti–PD-L1 IHC antibody clone 28-8 (Dako, Glostrup, Denmark) and tumor staining for PD-L1 was assessed using different thresholds (1%, 5%, and 10%) to define positive results [14, 15]. Here, CD274 is linked to neoplasm.